Identifying risks of dangerous heart rhythms in genetic heart conditions
Official title: Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation
Run by Vanderbilt University Medical Center · NCT06575881 · Data updated 2026-11-12
This study is trying to see if special heart tests can help find people with genetic heart conditions who are at risk for serious heart rhythm problems.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Vanderbilt University Medical Center Academic / other |
| Locations | 1 site (Nashville, Tennessee) |
| Status | Recruiting |
| Started | December 13, 2023 |
| Main results expected | December 2028 |
| Study ends | December 2029 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT06575881 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with atrial fibrillation, frequent premature ventricular contractions, or ventricular tachycardia before age 60, who are scheduled for catheter-based ablation procedures.
✕Probably not a fit
Patients with a prior diagnosis of a genetic cardiomyopathy or arrhythmia syndrome, or those with certain severe heart conditions, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to determine if electrophysiologic mapping and cardiac MRI can identify patients with genetic cardiomyopathies who are at high risk for developing dangerous ventricular arrhythmias. The study will assess the prevalence and mechanisms of inducible ventricular tachycardia, utilize pace-mapping to locate the origins of ventricular arrhythmias, and perform voltage mapping to identify low voltage scar substrates in the heart. Participants will undergo cardiac MRI and voltage mapping as part of the data collection process to enhance understanding of how genetic factors influence arrhythmia risk.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and management strategies for patients with genetic cardiomyopathies.
How similar studies have gone: Other studies have shown success in using genetic insights to inform clinical management of arrhythmias, making this approach both relevant and promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 and older * Diagnosed with AF, frequent PVCs, or VT before age 60 * Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation * Able to provide written, informed consent * P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control. Exclusion Criteria: * Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure * VUS in 'possibly pathogenic' subgroup (control group only) * Previous PVC or VT ablation * LVEF \<20% * Prosthetic mitral or aortic valve * Contraindication to heparin * Prior myocardial infarction
Where it's running
-
Vanderbilt University Medical Center
Nashville, Tennessee, United States Recruiting
Study contacts
- Study coordinator: Dakota Graherr, RN
- Email: dakota.grauherr@vumc.org
- Phone: 615-936-6069
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Arrhythmia mapping with a paddle-shaped multi-electrode catheter
This test uses a new high-density multi-electrode catheter to see if it can safely map atrial and ventricular arrhythmias in adults having catheter mapping and ablation.
-
Evaluating different approaches to cardiac pacing in patients
This study is testing different ways to place pacemakers in adults to see which methods work best and are safest for patients needing heart support.
-
Long-term outcomes for patients with cardiac arrhythmias
This study looks at how well treatments for heart rhythm problems work over time and what factors might affect their success for patients with conditions like atrial fibrillation and ventricular tachycardia.
-
Registry for monitoring heart conditions
This study is collecting health information from people with heart symptoms to see if it can help doctors catch heart problems earlier and understand them better.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
AI-powered ECG to help diagnose and locate tachycardia in patients with PSVT, WPW, PVC, or VT
A multicenter registry test whether an AI-enabled ECG analysis can help diagnose and localize tachycardia in adults with certain arrhythmias.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.